2025 GLP-1 Advocacy Wrapped
In late 2024 I started a petition for affordable access to GLP-1s. That grew to more than 27,000 signatures and unexpectedly opened the door to national and international media coverage.
What followed was a year of advocacy. Building the GLP-1 Studio, the Podcast, and founding the GLP-1 Collective nonprofit. It was a year of bonding with the community, learning how to keep moving failure after failure, and learning how to advocate for myself and for everyone else.
FDA's New Threat After Hims & Hers Launches Semaglutide Pill
On February 6, 2026, the FDA announced it intends to take “decisive steps” to restrict GLP-1 active pharmaceutical ingredients (APIs) used in non-FDA-approved compounded drugs, specifically calling out Hims & Hers and warning that companies could face legal action without further notice, including seizure and injunction.
Read about what happened and what it could mean for access to compounded GLP-1 medications.
Interview with Sabina Hemmi, Founder GLP Winner
In this episode, I sit down with Sabina Hemmi, founder of GLP Winner, to unpack the growing wave of federal and state legislation targeting compounded GLP-1 medications, including semaglutide and tirzepatide.
We break down what the Safe Drugs Act and related state bills could mean not just for weight-loss treatments, but for all compounding, from hospice and pediatric care to veterinary medicine. Sabina shares her personal journey as a long-term GLP-1 patient, why transparent pricing matters, and how patients can take action to protect access to the medications that have changed their lives.
Listen here to learn more and find out what this could mean for you.
Bills against Compounded Meds
Multiple states are pushing legislation that would devastate compounded medication access. Washington HB 2613, Florida SB 860/HB 877, and Mississippi SB 2542 would restrict or eliminate compounding entirely—not just for GLP-1s, but for children's medications, veterinary care, and end-of-life pain relief. Some bills limit pharmacies to just 20 "essential copy" prescriptions monthly while major facilities fill 10,000+ daily. Indiana's bill started terrifying but got amended after constituent calls proved our voices work. Virginia's bill was delayed a year. The federal SAFE Drugs Act (HR 6509), introduced by Indiana reps where Eli Lilly is headquartered, requires prescription reporting to fuel pharma litigation. If you're in an affected state, contact your representatives now—even five calls can change the outcome.
Visit GLP-1 Studio to see the current status and location of each bill.
Why Every Advocate Should Attend Your Weight Matters Conferences
This past weekend, I had the honor of attending an OAC’s social listening session and the Your Weight Matters regional conference in New Orleans.
Between the advocacy work and Mardi Gras opening day, it was an incredible experience that deepened my passion for obesity advocacy and for this community.
If there’s a regional event near you, go. These conferences aren’t just educational, they’re essential for anyone serious about advocacy and understanding the science behind the medications changing our lives. 💖
Learn more about the upcoming National Your Weight Matters event.